WILMINGTON, DE — Incyte (Nasdaq: INCY) has appointed Dave Gardner as Executive Vice President and Chief Strategy Officer. Gardner will join the company’s Executive Leadership Team, overseeing corporate strategy and business development.
“Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience,” said Bill Meury, president and CEO of Incyte. “He will play a pivotal role in developing a coherent and executable long-term growth strategy for the company and ensuring our portfolio decisions, business development and strategic partnerships position Incyte for sustainable value creation.”
Gardner brings more than two decades of experience in pharmaceutical and biotechnology investing and advising. Most recently, he served as partner on the Therapeutics Team at Rock Springs Capital Management, where he led strategy across oncology, neurology, immunology, and rare diseases. He previously spent a decade at BlackRock as vice president and equity research analyst focused on the healthcare sector.
Gardner holds an Executive MBA from Columbia Business School and a bachelor’s degree from the University of Virginia’s McIntire School of Commerce.
The appointment comes as Vijay Iyengar, M.D., executive vice president and head of global medical affairs and product and partnership strategy, retires after nine years with Incyte. Iyengar will remain with the company through year-end to support the transition.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.